Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Helius Medical Technologies ( (HSDT) ) has provided an update.
On September 22, 2025, Helius Medical Technologies announced its first acquisition of Solana (SOL) tokens as part of its digital asset treasury strategy, with over 760,190 SOL acquired at an average cost of $231. This move highlights Helius’s commitment to the Solana ecosystem and its strategy to maximize shareholder value by leveraging market conditions and retaining capital for future opportunities. The Solana blockchain, known for its rapid growth and high transaction volume, offers a ~7% native staking yield, making it a financially productive asset. Helius aims to support tokenized networks’ growth and security while continuing its neurotech and medical device operations.
The most recent analyst rating on (HSDT) stock is a Sell with a $21.00 price target. To see the full list of analyst forecasts on Helius Medical Technologies stock, see the HSDT Stock Forecast page.
Spark’s Take on HSDT Stock
According to Spark, TipRanks’ AI Analyst, HSDT is a Underperform.
Helius Medical Technologies is currently facing significant financial and operational challenges, as evidenced by its declining revenue, negative profitability, and poor cash flow. The technical analysis suggests mixed signals with short-term bullish momentum but long-term bearish trends. The company’s valuation is unattractive due to its negative P/E ratio and lack of dividend yield. These factors collectively result in a low overall stock score.
To see Spark’s full report on HSDT stock, click here.
More about Helius Medical Technologies
Helius Medical Technologies is a leading neurotech company in the medical device field, focusing on neurologic deficits through an orally applied technology platform that enhances the brain’s ability to engage physiologic compensatory mechanisms and promote neuroplasticity. Its first commercial product is the Portable Neuromodulation Stimulator.
Average Trading Volume: 759,808
Technical Sentiment Signal: Strong Sell
Current Market Cap: $25.99M
Learn more about HSDT stock on TipRanks’ Stock Analysis page.